{"result": "(\"entity\"<|>HORMONAS TIROIDEAS<|>EVENT<|>Hormonas tiroideas are thyroid hormones that may be involved in the context of hormonal treatments and conditions affecting women's health.)\n##\n(\"entity\"<|>HIPERANDROGENISMO<|>EVENT<|>Hiperandrogenismo refers to a condition characterized by excessive levels of androgens in the body, often associated with Polycystic Ovary Syndrome.)\n##\n(\"entity\"<|>INSULINORRESISTENCIA<|>EVENT<|>Insulinorresistencia is a condition where cells in the body become less responsive to insulin, often linked to metabolic syndrome and Polycystic Ovary Syndrome.)\n##\n(\"entity\"<|>SOP<|>EVENT<|>SOP, or Síndrome de Ovario Poliquístico, is the Spanish term for Polycystic Ovary Syndrome, a common hormonal disorder in women.)\n##\n(\"entity\"<|>ELEVADO HOMA<|>EVENT<|>Elevado HOMA refers to a high Homeostasis Model Assessment index, indicating insulin resistance, often seen in patients with Polycystic Ovary Syndrome.)\n##\n(\"entity\"<|>DISFUNCIÓN OVÁRICA<|>EVENT<|>Disfunción ovárica refers to ovarian dysfunction, which can be a symptom of Polycystic Ovary Syndrome.)\n##\n(\"entity\"<|>ECOGRAFÍA<|>EVENT<|>Ecografía is an imaging technique used to assess conditions like Polycystic Ovary Syndrome through the examination of ovaries.)\n##\n(\"entity\"<|>TAC<|>EVENT<|>TAC, or Tomografía Axial Computarizada, is a type of imaging used to investigate potential tumors in cases of severe hyperandrogenism.)\n##\n(\"entity\"<|>RNM<|>EVENT<|>RNM, or Resonancia Magnética, is a type of imaging used to investigate potential tumors in cases of severe hyperandrogenism.)\n##\n(\"entity\"<|>CARDIOPATÍA ISQUÉMICA<|>EVENT<|>Cardiopatía isquémica refers to ischemic heart disease, which can be a risk associated with metabolic syndrome.)\n##\n(\"entity\"<|>INSUFICIENCIA CARDÍACA<|>EVENT<|>Insuficiencia cardíaca refers to heart failure, which can be a risk associated with metabolic syndrome.)\n##\n(\"entity\"<|>ERITROCITOSIS<|>EVENT<|>Eritrocitosis is a condition characterized by an increased number of red blood cells, which can be a potential adverse effect of testosterone treatment.)\n##\n(\"entity\"<|>DISFUNCIÓN HEPÁTICA<|>EVENT<|>Disfunción hepática refers to liver dysfunction, which can be a potential adverse effect of testosterone treatment.)\n##\n(\"entity\"<|>CÁNCER DE MAMA<|>EVENT<|>Cáncer de mama refers to breast cancer, which can be a potential risk associated with testosterone treatment.)\n##\n(\"entity\"<|>CÁNCER DE ÚTERO<|>EVENT<|>Cáncer de útero refers to uterine cancer, which can be a potential risk associated with testosterone treatment.)\n##\n(\"entity\"<|>OBESIDAD ABDOMINAL<|>EVENT<|>Obesidad abdominal refers to abdominal obesity, which is a component of metabolic syndrome.)\n##\n(\"entity\"<|>DISLIPIDEMIA<|>EVENT<|>Dislipidemia refers to abnormal levels of lipids in the blood, which is a component of metabolic syndrome.)\n##\n(\"entity\"<|>HIPERTENSIÓN ARTERIAL<|>EVENT<|>Hipertensión arterial refers to high blood pressure, which is a component of metabolic syndrome.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: CLU) o    salival,  la pro-                                siguientes diagnósticos no tiene implicaciones sobre la decisión de interrumpir\n     lactina o las hormonas tiroideas. Ante un hiperandrogenismo grave, de rápida evolu-                                                                el tratamiento:\n     ción, o   con   niveles de testosterona plasmática total mayores                  de  2 ng/ml     (o de 1 ng/ml\n     en posmenopáusicas) o DHEA-S mayor de 6.000 ng/ml (>4.000 en posmenopáusicas) o                                                                    A. Síndrome de apneas del sueño.\n     de 2,5 veces el límite superior de la normalidad hay que indicar pruebas de imagen (eco-                                                           B. Pancreatitis.\n     grafía, TAC, RNM) en busca de una tumoración gonadal o suprarrenal. Considerando la rela-                                                          C. Cardiopatía isquémica con angina inestable e insuficiencia cardíaca.\n     ción existente entre el hiperandrogenismo ovárico y el hiperinsulinismo, las pacientes con                                                         D.  Eritrocitosis.\n     SOP son más resistentes a la insulina que las que no lo tienen, sean o no obesas. Podemos\n     objetivarlo mediante la determinación del índice HOMA, que se encontrará elevado, por la\n     presencia de criterios clínicos de síndrome metabólico (hipertensión arterial, dislipidemia,                                                       COMENTARIO\n     obesidad de predominio abdominal y alteraciones del metabolismo hidrocarbonado), y por                                                             La testosterona es el tratamiento hormonal de elección en el transexual varón (de mujer\n     su asociación con comorbilidades como la esteatosis hepática o el síndrome de apnea del                                                            a hombre) para conseguir virilización y amenorrea. Se usa generalmente por vía parente-\n     sueño. Las pacientes con disfunción ovárica e hiperandrogenismo bioquímico son las que                                                             ral (cipionato o propionato 100-200 mg/2 semanas, o undecanoato 1g/12 semanas), aun-\n     presentan más repercusiones clínicas y metabólicas. Las que presentan menos repercu-                                                               que también hay disponible en gel (1,6%, 50-100 mg/día) o parches transdérmicos (2,5-7,5\n     sión son las que solo padecen disfunción ovulatoria y ecografía de ovario poliquístico.                                                            mg/día), para alcanzar los niveles propios de los varones.\n     Referencias:                                                                                                                                       Con la testosterona se consiguen efectos androgénicos como el aumento de masa mus-\n     • Bulun SE. Physiology and Pathology of the female reproductive axis. En: Melmed S, Polonsky KS, Larsen P y Kronenberg H, eds.\n       13.ª ed. Williams Textbook of Endocrinology. Philadelphia: Elsevier; 2016. p. 590-663.                                                           cular y tejido magro con aumento de peso, aumento del pelo con distribución varonil (cara,\n     • Legro RS. Evaluation and Treatment of Polycystic Ovary Syndrome. En: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext                      tórax y abdomen), y disminución de la grasa cambiando a una distribución abdominal. La\n       [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK278959/ [Updated\n       2017 Jan 11].                                                                                                                                    voz se hace más grave, aumenta el clítoris y la libido. La mucosa del endometrio se atrofia\n     • Ortiz-Flores AE, Luque-Ramírez M, Escobar-Morreale HF. Síndrome de ovario poliquístico en la mujer adulta. Med Clin (Barc) [Internet].           por lo que suelen desaparecer las reglas.\n       2019. Disponible en: http://www.sciencedirect.com/science/article/pii/S0025775318307474\n                                                                                                                                                        No obstante, la testosterona tiene efectos adversos potenciales que es necesario vigilar,\n                                                                                                                                                        cuyos riesgos son:\n                                                                                                                                                        •  Muy altos: eritrocitosis.\n                                                                                                                                                        •  Moderadamente altos: disfunción hepática grave (aumento de transaminasas 3 veces más\n                                                                                                                                                           que en límite superior de normalidad), enfermedad coronaria o cerebrovascular, HTA, cán-\n                                                                                                                                                           cer de mama o útero.\n                                                                                                                                                        El aumento de la grasa visceral y la disminución de la grasa subcutánea asociada a insu-\n                                                                                                                                                        linorresistencia es perjudicial, por cuanto se asocia con                 el perfil del  síndrome metabólico\n                                                                                                                                                        (obesidad abdominal, dislipemia, HTA y alteraciones                  hidrocarbonadas), con mayor            morbi-\n                                                                                                                                                        mortalidad por enfermedad cardiovascular, agravado por el aumento de hematocrito. Es\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>BULUN SE<|>PERSON<|>Bulun SE is an author referenced in the context of the physiology and pathology of the female reproductive axis in medical literature.)\n##\n(\"entity\"<|>LEGRO RS<|>PERSON<|>Legro RS is an author referenced for the evaluation and treatment of Polycystic Ovary Syndrome in medical literature.)\n##\n(\"entity\"<|>ORTIZ-FLORES AE<|>PERSON<|>Ortiz-Flores AE is an author referenced in the context of Polycystic Ovary Syndrome in adult women in medical literature.)\n##\n(\"entity\"<|>POLYCYSTIC OVARY SYNDROME<|>EVENT<|>Polycystic Ovary Syndrome is a medical condition affecting women's reproductive health, characterized by hormonal imbalance and metabolic issues.)\n##\n(\"entity\"<|>TESTOSTERONE<|>ORGANIZATION<|>Testosterone is a hormone used in the treatment of transgender men to achieve virilization and amenorrhea.)\n##\n(\"entity\"<|>SINDROME METABOLICO<|>EVENT<|>Syndrome Metabolic refers to a cluster of conditions that increase the risk of heart disease, stroke, and diabetes.)\n##\n(\"relationship\"<|>BULUN SE<|>POLYCYSTIC OVARY SYNDROME<|>Bulun SE authored a reference discussing the physiology and pathology related to Polycystic Ovary Syndrome<|>7)\n##\n(\"relationship\"<|>LEGRO RS<|>POLYCYSTIC OVARY SYNDROME<|>Legro RS authored a reference discussing the evaluation and treatment of Polycystic Ovary Syndrome<|>7)\n##\n(\"relationship\"<|>ORTIZ-FLORES AE<|>POLYCYSTIC OVARY SYNDROME<|>Ortiz-Flores AE authored a reference discussing Polycystic Ovary Syndrome in adult women<|>7)\n##\n(\"relationship\"<|>TESTOSTERONE<|>POLYCYSTIC OVARY SYNDROME<|>Testosterone is used as a treatment for individuals with Polycystic Ovary Syndrome to manage symptoms<|>8)\n##\n(\"relationship\"<|>POLYCYSTIC OVARY SYNDROME<|>SINDROME METABOLICO<|>Polycystic Ovary Syndrome is associated with metabolic syndrome, increasing the risk of cardiovascular issues<|>6)\n<|COMPLETE|>"}]}